{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T17:04:56Z","timestamp":1780074296395,"version":"3.54.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Shanghai LianBio Development Co., Ltd"},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40119-026-00449-5","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T03:58:58Z","timestamp":1779335938000},"page":"185-200","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mavacamten in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy: Patient-Reported Health Status Analysis up to 78\u00a0Weeks in the EXPLORER-CN Study"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1140-4062","authenticated-orcid":false,"given":"Zhuang","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4583-3204","authenticated-orcid":false,"given":"Jian\u2019an","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoquan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1305-3980","authenticated-orcid":false,"given":"Wei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6287-3128","authenticated-orcid":false,"given":"Xiang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2905-2109","authenticated-orcid":false,"given":"Wei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6674-5537","authenticated-orcid":false,"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arteid","family":"Memaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimeng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Florea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1532-0029","authenticated-orcid":false,"given":"Shuyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"449_CR1","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1093\/ehjqcco\/qcae092","volume":"11","author":"SAC Schoonvelde","year":"2025","unstructured":"Schoonvelde SAC, Wiethoff I, Zwetsloot PP, et al. Loss of quality of life and increased societal costs in patients with hypertrophic cardiomyopathy: the AFFECT-HCM study. Eur Heart J Qual Care Clin Outcomes. 2025;11:174\u201385.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"449_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-081323","volume":"14","author":"S Shore","year":"2024","unstructured":"Shore S, Ervin C, Kosa K, et al. Qualitative interview study of patient-reported symptoms, impacts and treatment goals of patients with obstructive hypertrophic cardiomyopathy. BMJ Open. 2024;14:e081323.","journal-title":"BMJ Open"},{"key":"449_CR3","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s12955-020-01604-9","volume":"18","author":"R Capota","year":"2020","unstructured":"Capota R, Militaru S, Ionescu AA, et al. Quality of life status determinants in hypertrophic cardiomyopathy as evaluated by the Kansas City Cardiomyopathy Questionnaire. Health Qual Life Outcomes. 2020;18:351.","journal-title":"Health Qual Life Outcomes"},{"key":"449_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2217\/fca-2021-0091","volume":"18","author":"W Borsari","year":"2022","unstructured":"Borsari W, Davis L, Meiers E, Salberg L, Barbara M. Living with hypertrophic cardiomyopathy: a patient\u2019s perspective. Future Cardiol. 2022;18:43\u201350.","journal-title":"Future Cardiol"},{"key":"449_CR5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s41687-020-00269-8","volume":"4","author":"E Zaiser","year":"2020","unstructured":"Zaiser E, Sehnert AJ, Duenas A, Saberi S, Brookes E, Reaney M. Patient experiences with hypertrophic cardiomyopathy: a conceptual model of symptoms and impacts on quality of life. J Patient Rep Outcomes. 2020;4:102.","journal-title":"J Patient Rep Outcomes"},{"key":"449_CR6","first-page":"e558","volume":"142","author":"SR Ommen","year":"2020","unstructured":"Ommen SR, Mital S, Burke MA, et al. 2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020;142:e558\u2013631.","journal-title":"Circulation"},{"key":"449_CR7","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44:3503\u2013626.","journal-title":"Eur Heart J"},{"key":"449_CR8","first-page":"413","volume":"39","author":"F Zhu","year":"2023","unstructured":"Zhu F. An essential introduction to the 2023 guideline for diagnosis and treatment patients with hypertrophic cardiomyopathy. J Clin Cardiol (China). 2023;39:413\u20136.","journal-title":"J Clin Cardiol (China)"},{"key":"449_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2023.100622","volume":"2","author":"M Zhu","year":"2023","unstructured":"Zhu M, Reyes KRL, Bilgili G, et al. Medical therapies to improve left ventricular outflow obstruction and diastolic function in hypertrophic cardiomyopathy. JACC Adv. 2023;2:100622.","journal-title":"JACC Adv"},{"key":"449_CR10","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1001\/jamacardio.2023.3030","volume":"8","author":"Z Tian","year":"2023","unstructured":"Tian Z, Li L, Li X, et al. Effect of mavacamten on Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: the EXPLORER-CN randomized clinical trial. JAMA Cardiol. 2023;8:957\u201365.","journal-title":"JAMA Cardiol"},{"key":"449_CR11","unstructured":"Bristol Myers Squibb. CAMZYOS (mavacamten) capsules for oral use. Prescribing Information. 2025. United States Food and Drug Administration. https:\/\/packageinserts.bms.com\/pi\/pi_camzyos.pdf. Accessed June 2, 2025."},{"key":"449_CR12","unstructured":"Bristol-Myers Squibb Pharma EEIG. CAMZYOS (mavacamten) hard capsules. Summary of Product Characteristics. 2025. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/camzyos-epar-product-information_en.pdf. Accessed June 2, 2025."},{"key":"449_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168407","volume":"11","author":"JA Stern","year":"2016","unstructured":"Stern JA, Markova S, Ueda Y, et al. A small molecule inhibitor of sarcomere contractility acutely relieves left ventricular outflow tract obstruction in feline hypertrophic cardiomyopathy. PLoS One. 2016;11:e0168407.","journal-title":"PLoS One"},{"key":"449_CR14","doi-asserted-by":"publisher","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","volume":"292","author":"RF Kawas","year":"2017","unstructured":"Kawas RF, Anderson RL, Ingle SRB, Song Y, Sran AS, Rodriguez HM. A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle. J Biol Chem. 2017;292:16571\u20137.","journal-title":"J Biol Chem"},{"key":"449_CR15","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396:759\u201369.","journal-title":"Lancet"},{"key":"449_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","volume":"80","author":"MY Desai","year":"2022","unstructured":"Desai MY, Owens A, Geske JB, et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol. 2022;80:95\u2013108.","journal-title":"J Am Coll Cardiol"},{"key":"449_CR17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1253\/circj.CJ-24-0501","volume":"89","author":"H Kitaoka","year":"2025","unstructured":"Kitaoka H, Ieda M, Ebato M, et al. Phase 3 open-label study evaluating the efficacy and safety of mavacamten in Japanese adults with obstructive hypertrophic cardiomyopathy - the HORIZON-HCM study. Circ J. 2025;89:130\u20138.","journal-title":"Circ J"},{"key":"449_CR18","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","volume":"397","author":"JA Spertus","year":"2021","unstructured":"Spertus JA, Fine JT, Elliott P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397:2467\u201375.","journal-title":"Lancet"},{"key":"449_CR19","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","volume":"8","author":"MY Desai","year":"2023","unstructured":"Desai MY, Owens A, Wolski K, et al. Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial. JAMA Cardiol. 2023;8:968\u201377.","journal-title":"JAMA Cardiol"},{"key":"449_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-071473","volume":"13","author":"Z Tian","year":"2023","unstructured":"Tian Z, Wang F, Jin W, et al. Study design and rationale of EXPLORER-CN: a phase III, randomised, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy. BMJ Open. 2023;13:e071473.","journal-title":"BMJ Open"},{"key":"449_CR21","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","volume":"35","author":"CP Green","year":"2000","unstructured":"Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35:1245\u201355.","journal-title":"J Am Coll Cardiol"},{"key":"449_CR22","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","volume":"76","author":"JA Spertus","year":"2020","unstructured":"Spertus JA, Jones PG, Sandhu AT, Arnold SV. Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review. J Am Coll Cardiol. 2020;76:2379\u201390.","journal-title":"J Am Coll Cardiol"},{"key":"449_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2025.102587","volume":"13","author":"JA Spertus","year":"2025","unstructured":"Spertus JA, Jones PG, Butler J, Arnold SV. Minimally important Kansas City Cardiomyopathy Questionnaire changes across the spectrum of heart failure severity. JACC Heart Fail. 2025;13:102587.","journal-title":"JACC Heart Fail"},{"key":"449_CR24","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.jacc.2024.06.025","volume":"84","author":"MY Desai","year":"2024","unstructured":"Desai MY, Owens A, Wolski K, et al. Mavacamten in obstructive hypertrophic cardiomyopathy patients referred for septal reduction: health status analysis through week 56 in VALOR-HCM trial. J Am Coll Cardiol. 2024;84:1041\u20135.","journal-title":"J Am Coll Cardiol"},{"key":"449_CR25","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1161\/CIRCULATIONAHA.124.072445","volume":"151","author":"MY Desai","year":"2024","unstructured":"Desai MY, Wolski K, Owens A, et al. Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 128 results from VALOR-HCM. Circulation. 2024;151:1378\u201390.","journal-title":"Circulation"},{"key":"449_CR26","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030607","volume":"13","author":"A Masri","year":"2024","unstructured":"Masri A, Lester SJ, Stendahl JC, et al. Long-term safety and efficacy of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy: interim results of the PIONEER-OLE study. J Am Heart Assoc. 2024;13:e030607.","journal-title":"J Am Heart Assoc"},{"key":"449_CR27","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1161\/CIRCHEARTFAILURE.113.000359","volume":"6","author":"SM Joseph","year":"2013","unstructured":"Joseph SM, Novak E, Arnold SV, et al. Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction. Circ Heart Fail. 2013;6:1139\u201346.","journal-title":"Circ Heart Fail"},{"key":"449_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1161\/CIRCHEARTFAILURE.112.970053","volume":"6","author":"SV Arnold","year":"2013","unstructured":"Arnold SV, Spertus JA, Lei Y, et al. Use of the Kansas City Cardiomyopathy Questionnaire for monitoring health status in patients with aortic stenosis. Circ Heart Fail. 2013;6:61\u20137.","journal-title":"Circ Heart Fail"},{"key":"449_CR29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jchf.2022.03.002","volume":"10","author":"M Nassif","year":"2022","unstructured":"Nassif M, Fine JT, Dolan C, et al. Validation of the Kansas City Cardiomyopathy Questionnaire in symptomatic obstructive hypertrophic cardiomyopathy. JACC Heart Fail. 2022;10:531\u20139.","journal-title":"JACC Heart Fail"},{"key":"449_CR30","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cardfail.2024.08.061","volume":"31","author":"CFI Sherrod","year":"2025","unstructured":"Sherrod CFI, Spertus JA, Gosch K, et al. The Kansas City Cardiomyopathy Questionnaire in relation to New York Heart Association Class. J Cardiac Fail. 2025;31:481\u20134.","journal-title":"J Cardiac Fail"},{"key":"449_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/jpm15070274","volume":"15","author":"H-EV Nieh","year":"2025","unstructured":"Nieh H-EV, Roman YM. Major allele frequencies in CYP2C9 and CYP2C19 in Asian and European populations: a case study to disaggregate data among large racial categories. J Pers Med. 2025;15:274.","journal-title":"J Pers Med"},{"key":"449_CR32","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1136\/flgastro-2019-101391","volume":"12","author":"S Ansari","year":"2021","unstructured":"Ansari S, Haboubi H, Haboubi N. Obesity management for the gastroenterologist. Frontline Gastroenterol. 2021;12:235.","journal-title":"Frontline Gastroenterol"},{"key":"449_CR33","unstructured":"US Food and Drug Administration. Treatment for Heart Failure: Endpoints for Drug Development Guidance for Industry. Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research. https:\/\/www.fda.gov\/media\/128372\/download. Accessed June 2, 2025."},{"key":"449_CR34","unstructured":"World Health Organization. Coronavirus disease (COVID-19) pandemic. 2025. https:\/\/www.who.int\/europe\/emergencies\/situations\/covid-19. Accessed June 2, 2025."}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00449-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-026-00449-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00449-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T16:41:28Z","timestamp":1780072888000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-026-00449-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["449"],"URL":"https:\/\/doi.org\/10.1007\/s40119-026-00449-5","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Arteid Memaj, Yimeng Xie, Beth Pan, Victoria Florea, Jing Zheng, and Yue Zhong are employees of Bristol Myers Squibb and own stocks of Bristol Myers Squibb. Zhuang Tian, Xiaoyan Li, Liwen Li, Qing Zhang, Jian\u2019an Wang, Yunqi Shi, Daoquan Peng, Wei Ma, Ping Yang, Xiang Cheng, Wei Jin, Fang Wang, and Shuyang Zhang have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This trial was conducted in accordance with the principles of the Declaration of Helsinki and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guideline for Good Clinical Practice. Institutional review boards\/independent ethics committees (listed in Supplementary Table\u00a0\n                      \n                      ) at each site approved the protocol. The study complied with country-specific regulatory requirements relating to safety reporting to the regulatory authority, institutional review boards\/independent ethics committees, and investigators. All patients provided written informed consent to participate prior to entering the study. This study was funded by Shanghai LianBio Development Co., Ltd and Bristol Myers Squibb.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}